David A Isenberg


Affiliation: University College London
Country: UK


  1. Fernandes das Neves M, Irlapati R, Isenberg D. Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years. Rheumatology (Oxford). 2015;54:1403-7 pubmed publisher
    ..Age, sex, ethnicity, serological parameters and treatment received did not predict long-term remission. Renal flares can occur up to 15 years after a patient has gone into remission. ..
  2. Dias S, Rodriguez Garcia V, Nguyen H, Pericleous C, Isenberg D. Longer duration of B cell depletion is associated with better outcome. Rheumatology (Oxford). 2015;54:1876-81 pubmed publisher
    ..Cycles of BCD that induce longer duration of BCD are associated with better outcome. Lymphopenia may help to predict longer duration of the depletion and better outcome, although the mechanism is unclear. ..
  3. Morais S, du Preez H, Akhtar M, Cross S, Isenberg D. Musculoskeletal complications of haematological disease. Rheumatology (Oxford). 2016;55:968-81 pubmed publisher
  4. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878-1888 pubmed publisher
    ..The precise role of these newer therapies remains to be established. ..
  5. Croca S, Bassett P, Chambers S, Davari M, Alber K, Leach O, et al. IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. Arthritis Res Ther. 2015;17:26 pubmed publisher
    ..However, levels of IgG anti-apoA-1 vary over time and are associated with disease activity, treatment with high dose corticosteroid and not taking hydroxychloroquine. ..
  6. request reprint
    Alves S, Fasano S, Isenberg D. Autoimmune gastrointestinal complications in patients with systemic lupus erythematosus: case series and literature review. Lupus. 2016;25:1509-1519 pubmed
  7. Velo García A, Castro S, Isenberg D. The diagnosis and management of the haematologic manifestations of lupus. J Autoimmun. 2016;74:139-160 pubmed publisher
    ..In this review we consider the most common and characteristic haematological manifestations of SLE patients, focusing on their pathogenesis and management. ..
  8. request reprint
    Amaral Silva M, Cogollo E, Isenberg D. Why do patients with myositis die? A retrospective analysis of a single-centre cohort. Clin Exp Rheumatol. 2016;34:820-826 pubmed
    ..68, p=0.009) and UL+/LL+ (HR 0.16, p=0.027) were statistically significantly associated with survival. A good long-term survival is reported. Nevertheless, careful follow-up of myositis patients is important. ..
  9. Artim Esen B, Pericleous C, Mackie I, Ripoll V, Latchman D, Isenberg D, et al. Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. Arthritis Res Ther. 2015;17:47 pubmed publisher

More Information


  1. Cleanthous S, Isenberg D, Newman S, Cano S. Patient Uncertainty Questionnaire-Rheumatology (PUQ-R): development and validation of a new patient-reported outcome instrument for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in a mixed methods study. Health Qual Life Outcomes. 2016;14:33 pubmed publisher
    ..82 - 0.93). The PUQ-R has been developed and evaluated specifically for patients with SLE and RA. By quantifying uncertainty, the PUQ-R has the potential to support evidence-based management programmes and research. ..
  2. Fasano S, Gordon P, Hajji R, Loyo E, Isenberg D. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford). 2017;56:26-36 pubmed publisher
    ..We identified 458 patients with myositis treated with RTX. We found a rate of response to RTX of 78.3%. RTX can play a role in the management of patients with myositis, at least in those with positive myositis-specific autoantibodies. ..
  3. request reprint
    Morais S, Isenberg D. A study of the influence of ethnicity on serology and clinical features in lupus. Lupus. 2017;26:17-26 pubmed
    ..Serositis, joint and neurological involvement were more frequently diagnosed in the South Asian patients. Anti-ENA antibodies were frequently associated with the Afro-Caribbean patients. ..
  4. Fritsch C, Hoebeke J, Dali H, Ricchiuti V, Isenberg D, Meyer O, et al. 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. Arthritis Res Ther. 2006;8:R4 pubmed
    ..IgG antibodies to Ro52 peptides 1-13, 107-122, 277-292 and 365-382 may therefore represent important biomarkers to predict a complication in pregnant lupus women with Ro52 antibodies. ..
  5. Chinoy H, Salway F, Fertig N, Shephard N, Tait B, Thomson W, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther. 2006;8:R13 pubmed
    ..In conclusion, these findings support the notion that myositis patients with differing myositis serology have different immunogenetic profiles, and that these profiles may define specific myositis subtypes. ..